Tolerance and pharmacodynamics phase Ⅰ clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin's lymphoma.
10.3760/cma.j.issn.0253-2727.2018.04.013
- Author:
Bo JIANG
1
;
Jun Yuan QI
;
Ming Yuan SUN
;
Zeng Jun LI
;
Wei LIU
;
Li Jun LIU
;
Feng Kui ZHANG
;
Lu Gui QIU
Author Information
1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
- Publication Type:Journal Article
- Keywords:
Chimeric anti-CD20 monoclonal antibody;
Non-Hodgkin’s lymphoma;
Phase Ⅰ study
- MeSH:
Adult;
Animals;
Antibodies, Monoclonal;
Antigens, CD20;
Antineoplastic Agents;
Child;
Humans;
Lymphoma, B-Cell;
Lymphoma, Non-Hodgkin/drug therapy*;
Mice;
Rituximab
- From:
Chinese Journal of Hematology
2018;39(4):320-324
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the tolerance and safety of a human-mouse chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients achieved objective response with CD20(+) B-cell non-Hodgkin's lymphoma (NHL). Methods: Nine patients with CD20(+) B-cell NHL received dose-escalating IBI301 infusions (250 mg/m(2), n=3; 375 mg/m(2), n=3; 500 mg/m(2), n=3, respectively). The data of all patients were collected for safety analyses. The median exposures of 125 mg/m(2), 375 mg/m(2), 500 mg/m(2) dose groups were 243, 690 and 980 mg, respectively. Safety and tolerability were evaluated by monitoring adverse events (AE). The ratios of CD19(+), CD20(+) B cells and the levels IgG and IgM were detected to evaluate the pharmacodynamics. Results: Totally 52 events of AE were observed, including 18 events of AE in 125 mg/m(2) group, 14 events of AE in 375 mg/m(2) group and 20 events of AE in 500 mg/m(2) group, respectively. There were 26 adverse reactions of 52 cases of AE, 22 reactions were judged to be probably related to IBI301, and 4 reactions were not probably related to IBI301, all disappeared or returned to baseline levels. Common AE in this study included decreased WBC, upper respiratory infection, decreased neutrophil count, dyspepsia, hyperuricemia, paresthesia, oral mucositis and dizziness. No patients quitted or trial discontinued. No severe AE (SAE) were reported. No dose-limiting toxicity (DLT) events were observed in the study. The ratio of CD20(+) and CD19(+) B cells decreased in all subjects. There was no significant changes of the levels of IgG and IgM. Conclusions: The single dose of IBI301 injection was well tolerated, and the AE occurred in the patients recovered. No SAE were reported, No DLT events were observed in the study. The IBI301 caused an elimination of the peripheral CD20-expressing B cells in all patients. Clinical trial registration: Chinadrugtrials, CTR20140762.
